We’ve sliced and diced our portfolio into distinct “trends” that define our edge.
We are pleased to report that as of April 2021 the SOSV Climate Tech 100 have raised $1.85 billion from investors and have a market cap of $5.65 billion. The average company is four years old. SOSV (our parent fund) has invested $89 million in these companies and was in most cases the first investor, though we continued investing through early rounds.
IndieBio has never been one to shy away from the riskiest and most impactful investments for our planet. In fact, we embrace them.
Boosting female representation in the startup world is an ongoing challenge, but we’re dedicated to gender balance, not only because it’s the right thing to do, but because we would be dismissing impressive companies otherwise. We’ve found that more gender balance leads to better workplace culture and better ideas being exchanged.
Future of Food
It’s not just that we can make meat and fish in the lab, or with mushrooms and chickpeas. It’s not just that AI can predict the best plant ingredients to make the best tasting milk and yogurt. And it’s not just that yeast can be fermented to produce the healthier and better food preservatives. We’re diving deep every day into the foods that will satisfy novelty-seekers and conventionalists alike.
We’re putting big bets on the newest technologies and trends we think are ahead of the curve.
Future of Medicine
Medicine ain’t what it used to be. Today, bloodletting, skull-drilling and giving children cocaine for toothaches are relics of the past. Tomorrow, so too will addictive opioids, chemotherapy, and psychiatric drugs that are non-selectively bathing our bodies in chemicals.
The future of medicine is an exciting one, and we’re excited to share the most exciting technologies that enable the next wave of medicine and healthcare.
Our mission has always been Human and Planetary Health from the beginning, so it’s hard to say which of our companies are “impact” companies (in some ways, they all are).
Here, we narrowed down the startups that are directly addressing sustainability issues, improving public health, mitigating inequality, and democratizing access to infrastructure and technologies.
Every season of the year, a new batch and about one-sixth of our alumni are in raise mode. These companies are currently raising and would love to talk to interested investors. We can set up those meetings or you can contact the companies directly.
In the last few years, aptamers linked to CRISPR have brought programmable logic to drug design. However, the logic is primitive – once turned on, CRISPR remains on. Wayfinder is working on RNA-biosensors so that drugs can continuously sense their microenvironment, and turn modalities like CRISPR both on and off in response to what they […]
Pesticides are always a compromise: if you kill the mosquitos, you end up killing the bees too. Pyrone discovered a rare natural compound that controls mosquitos and other pests not by killing them, but by temporarily stunning them. Already fast-tracked by the EPA and being tested by the USDA in Gainesville, Pyrone is now scaling […]
In the canon of cultured meat, it’s all about reducing the cost of the Growth Factors. Grand Bio defies this doctrine. It’s like the cars we all drive. You can reduce the cost of gas. Or you can help the car drive farther on a gallon. Grand Bio sells affordable media supplements. Their activators can […]
There’s two general concerns around molecular farming, where animal proteins are grown in field crops. First, the extraction and purification. Second, the regulatory landscape for transgenic crops amidst other farmland. Veloz Bio doesn’t use the farm. And the founders are experts at extraction and membrane purification. Without the need of bioreactors, they can develop and scale […]
The TômTex mission is to create innovative material designs that parallel lifecycles observed in nature and serve as alternatives to the production methods that have contributed to our world’s environmental crisis. Our revolutionary bio-based materials offer a sustainable, accessible, and practical alternative to currently available commercial material options.
Biological sample preparation has not kept pace with the dramatic changes in analytical techniques. Nowhere is this more evident than in DNA sample prep, which continues to be a low throughput process serving high throughput next-generation DNA sequencing. This mismatch is limiting the accelerated uptake of next generation sequencing. Inso Bio envisions a future of […]